Literature DB >> 22778394

IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.

Kai Sun1, Hui-Hua Hsiao, Minghui Li, Erik Ames, Myriam Bouchlaka, Lisbeth A Welniak, Takeshi Hagino, Jared Jagdeo, Chien-Chun Pai, Mingyi Chen, Bruce R Blazar, Mehrdad Abedi, William J Murphy.   

Abstract

Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation. It has been previously reported that lung GVHD severity directly correlates with the expansion of donor Th17 cells in the absence of IFN-γ. However, the consequence of Th17-associated lung GVHD in the presence of IFN-γ has not been well characterized. In the current study, T cells from IFN-γ receptor knockout (IFN-γR(-/-)) mice, capable of producing IFN-γ but unable to signal in response to IFN-γ, have been used to elucidate further the role of IFN-γ in GVHD. We found the transfer of donor T cells from either IFN-γR(-/-) or IFN-γ knockout (IFN-γ(-/-)) mice resulted in significant increases in donor Th17 cells in the lung. Marked increases in IL-4-producing Th2 cells infiltrating the lungs were also observed in the mice of donor IFN-γR(-/-) T cells. Notably, despite the presence of these cells, these mice did not show the severe immune-mediated histopathological lung injury observed in mice receiving donor IFN-γ(-/-) T cells. Increases in lung GVHD did occur in mice with donor IFN-γR(-/-) T cells when treated in vivo with anti-IFN-γ demonstrating that the cytokine has a protective role on host tissues in GVHD. A survival benefit from acute GVHD was also observed using donor cells from IFN-γR(-/-) T cells compared with control donors. Importantly, tumor-bearing mice receiving IFN-γR(-/-) T cells versus wild-type donor T cells displayed similar graft-versus-tumor (GVT) effects. These results demonstrate the critical role of IFN-γ on host tissues and cell effector functions in GVHD/GVT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22778394      PMCID: PMC3509544          DOI: 10.4049/jimmunol.1102853

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation.

Authors:  K R Cooke; G R Hill; A Gerbitz; L Kobzik; T R Martin; J M Crawford; J P Brewer; J L Ferrara
Journal:  Transplantation       Date:  2000-07-27       Impact factor: 4.939

Review 2.  Expanding the effector CD4 T-cell repertoire: the Th17 lineage.

Authors:  Laurie E Harrington; Paul R Mangan; Casey T Weaver
Journal:  Curr Opin Immunol       Date:  2006-04-17       Impact factor: 7.486

Review 3.  Th17 cell differentiation: the long and winding road.

Authors:  Mandy J McGeachy; Daniel J Cua
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

4.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.

Authors:  Heon Park; Zhaoxia Li; Xuexian O Yang; Seon Hee Chang; Roza Nurieva; Yi-Hong Wang; Ying Wang; Leroy Hood; Zhou Zhu; Qiang Tian; Chen Dong
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

5.  Transforming growth factor-beta induces development of the T(H)17 lineage.

Authors:  Paul R Mangan; Laurie E Harrington; Darrell B O'Quinn; Whitney S Helms; Daniel C Bullard; Charles O Elson; Robin D Hatton; Sharon M Wahl; Trenton R Schoeb; Casey T Weaver
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

6.  Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

Authors:  Y G Yang; B R Dey; J J Sergio; D A Pearson; M Sykes
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

7.  Interferon-gamma regulates idiopathic pneumonia syndrome, a Th17+CD4+ T-cell-mediated graft-versus-host disease.

Authors:  Nora Mauermann; Julia Burian; Christophe von Garnier; Stefan Dirnhofer; Davide Germano; Christine Schuett; Michael Tamm; Roland Bingisser; Urs Eriksson; Lukas Hunziker
Journal:  Am J Respir Crit Care Med       Date:  2008-05-29       Impact factor: 21.405

8.  IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract.

Authors:  Angela C Burman; Tatjana Banovic; Rachel D Kuns; Andrew D Clouston; Amanda C Stanley; Edward S Morris; Vanessa Rowe; Helen Bofinger; Renae Skoczylas; Neil Raffelt; Olivier Fahy; Shaun R McColl; Christian R Engwerda; Kelli P A McDonald; Geoffrey R Hill
Journal:  Blood       Date:  2007-04-20       Impact factor: 22.113

9.  Adenovirus type 5 induces vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells.

Authors:  S Ganguly; S Manicassamy; J Blackwell; B Pulendran; R R Amara
Journal:  Mucosal Immunol       Date:  2011-02-02       Impact factor: 7.313

10.  Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.

Authors:  Dror Luger; Phyllis B Silver; Jun Tang; Daniel Cua; Zoe Chen; Yoichiro Iwakura; Edward P Bowman; Nicole M Sgambellone; Chi-Chao Chan; Rachel R Caspi
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307

View more
  7 in total

1.  Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding.

Authors:  Parvathi Ranganathan; Apollinaire Ngankeu; Nina C Zitzer; PierPaolo Leoncini; Xueyan Yu; Lucia Casadei; Kishore Challagundla; Dawn K Reichenbach; Sabrina Garman; Amy S Ruppert; Stefano Volinia; Jessica Hofstetter; Yvonne A Efebera; Steven M Devine; Bruce R Blazar; Muller Fabbri; Ramiro Garzon
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

2.  Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels.

Authors:  Chien-Chun Steven Pai; Hui-Hua Hsiao; Kai Sun; Mingyi Chen; Takeshi Hagino; Joseph Tellez; Christine Mall; Bruce R Blazar; Arta Monjazeb; Mehrdad Abedi; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-23       Impact factor: 5.742

3.  Risk model incorporating donor IL6 and IFNG genotype and gastrointestinal GVHD can discriminate patients at high risk of steroid refractory acute GVHD.

Authors:  N Alam; W Xu; E G Atenafu; J Uhm; M Seftel; V Gupta; J Kuruvilla; J H Lipton; H A Messner; D D H Kim
Journal:  Bone Marrow Transplant       Date:  2015-03-16       Impact factor: 5.483

Review 4.  The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

5.  Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD.

Authors:  Christian M Capitini; Nicole M Nasholm; Christopher D Chien; Shannon M Larabee; Haiying Qin; Young K Song; Peter J Klover; Lothar Hennighausen; Javed Khan; Terry J Fry
Journal:  Blood       Date:  2014-07-25       Impact factor: 22.113

Review 6.  The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations.

Authors:  Chenchen Zhao; Yi Zhang; Hong Zheng
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

Review 7.  T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?

Authors:  Julia Campe; Evelyn Ullrich
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.